OGN - What to expect from Organon Q4 earnings

• Organon ( NYSE: OGN ) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open.
• The consensus EPS Estimate is $0.91 (-33.6% Y/Y) and the consensus Revenue Estimate is $1.5B (-6.3% Y/Y).
• Over the last 1 year, OGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.
• Over the last 3 months, EPS estimates have seen 2 upward revisions and 3 downward. Revenue estimates have seen 1 upward revision and 3 downward.
• The company expects the Established Brands to report a slight growth on a constant currency basis this year despite a potential impact in Q4 from participating in China’s bulk drug procurement program.
• Citing ongoing currency headwinds, Organon ( OGN ) narrowed its 2022 revenue guidance to $6.1B – $6.2B from $6.1B – $6.3B, estimated three months ago. The current consensus expects the company to report $6.19B in revenue.
• During the quarter, Organon launched Ontruzant, a biosimilar of Roche's cancer drug Herceptin, to treat Canadian adults with early breast cancer ( EBC ), metastatic breast cancer ( MBC ) and metastatic gastric cancer ( MGC ).

For further details see: